Fedratinib Attenuates Bleomycin-Induced Pulmonary Fibrosis via the JAK2/STAT3 and TGF-β1 Signaling Pathway |
| |
| Authors: | Hao Ruan Jiaoyan Luan Shaoyan Gao Shuangling Li Qiuyan Jiang Rui Liu Qing Liang Ruiqin Zhang Fangxia Zhang Xiaohe Li Honggang Zhou Cheng Yang |
| |
| Institution: | 1.State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300000, China; (H.R.); (J.L.); (S.G.); (S.L.); (Q.J.); (R.L.); (Q.L.); (R.Z.); (F.Z.); (X.L.); (C.Y.);2.High-Throughput Molecular Drug Screening Centre, Tianjin International Joint Academy of Biomedicine, Tianjin 300070, China |
| |
| Abstract: | Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease with multiple causes, characterized by excessive myofibrocyte aggregation and extracellular matrix deposition. Related studies have shown that transforming growth factor-β1 (TGF-β1) is a key cytokine causing fibrosis, promoting abnormal epithelial–mesenchymal communication and fibroblast-to-myofibroblast transition. Fedratinib (Fed) is a marketed drug for the treatment of primary and secondary myelofibrosis, targeting selective JAK2 tyrosine kinase inhibitors. However, its role in pulmonary fibrosis remains unclear. In this study, we investigated the potential effects and mechanisms of Fed on pulmonary fibrosis in vitro and in vivo. In vitro studies have shown that Fed attenuates TGF-β1- and IL-6-induced myofibroblast activation and inflammatory response by regulating the JAK2/STAT3 signaling pathway. In vivo studies have shown that Fed can reduce bleomycin-induced inflammation and collagen deposition and improve lung function. In conclusion, Fed inhibited inflammation and fibrosis processes induced by TGF-β1 and IL-6 by targeting the JAK2 receptor. |
| |
| Keywords: | fedratinib pulmonary fibrosis JAK2/STAT3 transforming growth factor-β 1 fibroblast-to-myofibroblast transition |
|
|
